This review, aims to assess the ability of CSF tau biomarkers (t-tau and p-tau) and the CSF tau (t-tau or p-tau)/ABeta ratio to enable the detection of Alzheimer’s disease pathology in patients with mild cognitive impairment (MCI).
Parkinson’s disease comes in many flavors, posing a challenge for clinical trials. Knowing how the disease progresses may improve chances of success. A longitudinal study from the LRRK2 Ashkenazi Jewish Consortium provides just such data.
https://www.alzforum.org/news/research-news/does-daytime-drowsiness-foreshadow-av-accumulation
Paul Brownbill, is from the University of South Wales, in his blog he talks about ‘Quality of Life and the Role of Communal Space in Sheltered Housing’
With Pfizer shutting down its neuroscience unit and a long list of failed late-stage trials, the sheer difficulty of improving the treatment of Alzheimer’s disease has become painfully clear. How can researchers crack the mystery of this much-feared neurodegenerative disease?
Brain imaging reveals how inherited Alzheimer’s unfolds decades before symptoms, beginning with amyloid build-up, followed by metabolic decline and atrophy.
I am a researcher in the School of Medicine at Cardiff University. My background is in nursing, but I have been an applied health researcher for the past 5 years,…
Planning an overview of systematic reviews? Learn to frame clear questions, set relevant objectives, involve stakeholders and develop a transparent protocol.
A study of 30.5 million people links alcohol use disorders to triple the risk of dementia and more than half of cases diagnosed before age 65.
Dementia Researcher
Alz Forum